Mirati Therapeutics, Inc. logo

Mirati Therapeutics, Inc.

NASDAQ:MRTX

Overview | Financials
Company Name Mirati Therapeutics, Inc.
Symbol MRTX
Currency USD
Price 58.7
Market Cap 4,117,669,755
Dividend Yield 0%
52-week-range 27.3 - 64.41
Industry Biotechnology
Sector Healthcare
CEO Dr. Charles M. Baum M.D., Ph.D.
Website https://www.mirati.com

An error occurred while fetching data.

About Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and

Related Stocks

Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

NTLA

9.71 USD

Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

RARE

40.98 USD

Karuna Therapeutics, Inc. logo

Karuna Therapeutics, Inc.

KRTX

329.83 USD

Inari Medical, Inc. logo

Inari Medical, Inc.

NARI

79.4 USD

Patterson Companies, Inc. logo

Patterson Companies, Inc.

PDCO

30.89 USD

Cytokinetics, Incorporated logo

Cytokinetics, Incorporated

CYTK

46.87 USD

Blueprint Medicines Corporation logo

Blueprint Medicines Corporation

BPMC

104.89 USD

Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc.

VIR

10.5 USD

Financials

Numbers are in millions USD

Numbers are in millions USD